secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0000939767-24-000149
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q3 revenue $539.5M, EPS $0.40; raises FY 2024 guidance
---------------------------------------------------------------

- Q3 net product revenue $478.1M (cabozantinib franchise) vs $426.5M YoY, +12%.
- GAAP diluted EPS $0.40, non-GAAP diluted EPS $0.47; prior year $0.00 and $0.10.
- Raises 2024 total revenue and net product revenue guidance on strong commercial performance.
- Favorable U.S. District Court ruling on cabozantinib patent litigation received.
- New collaboration with Merck adds two phase 3 trials for zanzalintinib in renal cell carcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000149/0000939767-24-000149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000149/exel-20241029.htm
  HTML page:      https://secwatch.observer/filing/0000939767-24-000149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer